Chronic Obstructive Pulmonary Disease, One-lung Ventilation
Conditions
Brief summary
One-lung ventilation (OLV) is essential part of anesthesia during thoracic procedures. However, OLV induces a drastic increase of intrapulmonary shunt due to maintained pulmonary perfusion through the nonventilated lung, which may result in severe hypoxemia. Although the protective mechanisms of hypoxic pulmonary vasoconstriction favorably modulate pulmonary perfusion to the ventilated lung, the effect is attenuated in patients with history of chronic obstructive pulmonary disease (COPD), which alters compliance of the pulmonary artery. Salbutamol is a selective short-acting beta2-agonist and when inhaled during OLV, it acts selectively on the pulmonary vasculature reducing pulmonary vascular resistance of well-ventilated lung. We hypothesized that inhaled salbutamol would alleviate ventilation-perfusion mismatch during OLV of COPD patients, and aimed to assess the effects of salbutamol on oxygenation in these patients.
Interventions
After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
DRUG2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline
After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patient age 40\ 80yrs, scheduled for videoscope-assisted pulmonary lobectomy * American Society of Anesthesiologists Class III 또는 IV * Moderate or more severe COPD according to GOLD criteria (FEV1/FVC\<70%, FEV1\<80%)
Exclusion criteria
* New York Heart Association class \>II * AST level ≥100 IU/mL or ALT ≥ level 50 IU/L * Creatinine clearance \< 30mL/min * History of severe coronary artery occlusive disease, unstable angina, or recent myocardial infarction within 6 months * History of pulmonary hypertension or pulmonary edema * History of cerebrovascular accident within 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PaO2 (partial pressure of arterial oxygen) to FiO2 (fraction of inspired oxygen) ratio (P/F ratio) | Thirty minutes after the completion of drug inhalation | The P/F ratio is a widely-used objective tool to identify hypoxemic respiratory failure when supplemental oxygen has been administered. It can be used to evaluate the effect of salbutamol on oxygenation during OLV. |
Countries
South Korea
Outcome results
None listed